Company / Net Income
ImmunityBio, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$351.4M
FY2025
5-year range
-$583.2M / -$157.8M
FY2021-FY2025
Trend
+15.0%
vs FY2024
Sector context
#185 of 216
Health Care
What the data says
ImmunityBio, Inc.'s net income of -$351M is lower than 86% of companies in the Health Care sector (FY2025). Net Income has fluctuated over the past 10 years, ranging from -$583M in FY2023 to -$6M in FY2016.
Based on SEC 10-K filings.
-$351M in FY2025.
Improved from -$583M to -$351M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 216This company -$351.4M Sector average $454.1M
▼
-177.4% below sector average
Key checks
Key Insights
- In FY2025, net income increased 15.0% year-over-year.
- Ranks #185 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2016.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -7.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$351.4M | +15.0% |
| FY2024 | -$413.6M | +29.1% |
| FY2023 | -$583.2M | -40.0% |
| FY2022 | -$416.6M | -164.0% |
| FY2021 | -$157.8M | +28.9% |
| FY2020 | -$221.9M | -40.6% |
| FY2019 | -$157.8M | -30.6% |
| FY2018 | -$120.8M | +49.0% |
| FY2017 | -$236.9M | -3729.8% |
| FY2016 | -$6.2M | +97.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026